Log in to save to my catalogue
Log in to save to my catalogue

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

| Ask | Become a Library member

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6820050

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

About this item

Publication information

Publisher

London: Nature Publishing Group UK

Subjects

Subjects and topics

More information

Scope and Contents

Contents

The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been described. We analyzed outcomes of 275 MM patients at 14 academic centers with disease refractory to...

Alternative Titles

Full title

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

Authors, Artists and Contributors

Author / Creator

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6820050

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6820050

Other Identifiers

ISSN

0887-6924

E-ISSN

1476-5551

DOI

10.1038/s41375-019-0435-7

How to access this item

Log in as a Library member

Full text available

About resource

View in old catalogue

Connecting people and collections